CN1694694A - 神经性厌食症(an)和贪食症的治疗 - Google Patents

神经性厌食症(an)和贪食症的治疗 Download PDF

Info

Publication number
CN1694694A
CN1694694A CNA038251698A CN03825169A CN1694694A CN 1694694 A CN1694694 A CN 1694694A CN A038251698 A CNA038251698 A CN A038251698A CN 03825169 A CN03825169 A CN 03825169A CN 1694694 A CN1694694 A CN 1694694A
Authority
CN
China
Prior art keywords
epa
purposes
treatment
acid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038251698A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·F·霍罗宾
阿格尼丝·艾顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laxdale Ltd
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1694694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of CN1694694A publication Critical patent/CN1694694A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CNA038251698A 2002-09-16 2003-09-16 神经性厌食症(an)和贪食症的治疗 Pending CN1694694A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0221480.7 2002-09-16
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia

Publications (1)

Publication Number Publication Date
CN1694694A true CN1694694A (zh) 2005-11-09

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038251698A Pending CN1694694A (zh) 2002-09-16 2003-09-16 神经性厌食症(an)和贪食症的治疗

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276262A (zh) * 2018-07-30 2019-01-29 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005046668A1 (ja) * 2003-11-14 2005-05-26 Mochida Pharmaceutical Co., Ltd. 言語障害予防・治療剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
CA2672513C (en) 2007-02-15 2010-05-25 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
BRPI1011883A2 (pt) * 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
AU2012214260A1 (en) * 2011-02-11 2013-07-25 E. I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
WO2019153073A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210130897A1 (en) * 2018-04-16 2021-05-06 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
US11166933B2 (en) 2018-05-03 2021-11-09 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
US12144786B2 (en) 2020-03-27 2024-11-19 Homeostasis Therapeutics LLC Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276262A (zh) * 2018-07-30 2019-01-29 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统

Also Published As

Publication number Publication date
NZ538793A (en) 2007-05-31
NO20051847L (no) 2005-04-15
ZA200502161B (en) 2005-09-15
US20060135608A1 (en) 2006-06-22
PL375726A1 (en) 2005-12-12
WO2004024136A1 (en) 2004-03-25
KR20050042823A (ko) 2005-05-10
EP1556028A1 (en) 2005-07-27
CA2499142A1 (en) 2004-03-25
BR0317857A (pt) 2005-12-06
JP2006503031A (ja) 2006-01-26
RS20050226A (sr) 2007-09-21
MXPA05002943A (es) 2005-06-03
AU2003269138A1 (en) 2004-04-30
GB0221480D0 (en) 2002-10-23
HRP20050245A2 (en) 2005-10-31
IS7744A (is) 2005-03-15
RU2330653C2 (ru) 2008-08-10
TW200410682A (en) 2004-07-01
RU2005107416A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
Gastaut Dictionary of epilepsy
Haas et al. Therapeutic effects of a ketogenic diet in Rett syndrome
RU2330653C2 (ru) Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии
Hillard Bulimia and diabetes: a potentially life-threatening combination
Nishioka et al. The concept of aggressive nutrition therapy and clinical indication: a position paper
Al-Mosawi The treatment of a child with birth asphyxia induced brain atrophy, adrenal hemorrhage, and bi-lateral hyperoxaluric nephrocalcinosis: A challenging case and a unique experience
Garcia‐Cruz et al. The Myhre syndrome: report of two cases
CN110420225A (zh) 一种用于防治骨关节炎的组合物及其制备方法和应用
Janssen Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night?
JP6368368B2 (ja) ｐ−アニスアルデヒドを使用する組成物及び方法
JP2016525134A (ja) チグリンアルデヒドを使用する組成物及び方法
Cott Controlled fasting treatment for schizophrenia
CN102085357B (zh) 原料含有水蛭素、纤溶素的药物的用途
Steadman Herpes simplex mimicking functional psychosis
Fauteck The Magic of Melatonin: How this Amazing Hormone Will Help You Sleep, Reduce Pain, Relieve Anxiety, Slow Aging, and Much More
JP2016525133A (ja) クミンアルデヒドを使用する組成物及び方法
US20200261485A1 (en) Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions
Cobb Stiff man syndrome: is the lesion at spinal cord or brain stem level
RU2282453C2 (ru) Способ терапии больных сахарным диабетом ii типа
Anderson Development & Changes in Digestion & Sleep
Kumar Social and preventive health administration
Stunkard et al. Surgical treatment of obesity
Liggan et al. Taking care of our folks: a manual for family members caring for the black elderly
EA012557B1 (ru) Способ коррекции веса тела человека
Cadwalader IDIOPATHIC EPILEPSY COMPLICATED BY MOTOR APHASIA AND DIPLEGIA, WITH NECROPSY.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication